posted on 2012-08-23, 00:00authored byH Iland, K Bradstock, S Supple, A Catalano, M Collins, M Hertzberg, P Browett, A Grigg, F Firkin, A Hugman, John Reynolds, J Di Iulio, C Tiley, K Taylor, R Filshie, M Seldon, J Taper, J Szer, J Moore, J Bashford, J Seymour
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)